Martina Imbimbo
University of Milan
CancerInternal medicineSurgeryPathologyOncologyRetrospective cohort studyIntensive care medicineImmunohistochemistryLung cancerHead and neck cancerChemotherapyImmunotherapyMucositisSorafenibSalivary glandDiseaseAdenoid cystic carcinomaConcomitantProgression-free survivalAdenocarcinomaNon small cellLocally advancedIn patientImmune checkpoint inhibitorsMutationCancer researchMedicineImmune system
52Publications
16H-index
598Citations
Publications 51
Newest
#1Diego SignorelliH-Index: 18
#2Claudia ProtoH-Index: 19
Last. Monica GanzinelliH-Index: 21
view all 20 authors...
Background Malignant pleural mesothelioma (MPM) is an aggressive tumor but approximately 12% of patients survive more than 3 years. The biological differences underlying better outcomes are not known. Several targeted agents and immunotherapy have been ineffective. Hedgehog (Hh) is one emerging pathway. We compared the biological profiles of patients with different survival, investigating the most frequently altered genes, including the Hh pathway. Methods We analyzed 56 MPM. A 36-month overall ...
Source
#1Giulia Galli (University of Milan)H-Index: 10
#1Giulia GalliH-Index: 92
Last. Giuseppe Lo RussoH-Index: 20
view all 10 authors...
Introduction:Immunotherapy has shown efficacy in the treatment of different malignancies. Nivolumab, an immune checkpoint inhibitor directed against programmed death-1, has been approved for non-sm...
3 CitationsSource
#1Giulia GalliH-Index: 10
#1Giulia GalliH-Index: 92
Last. Giuseppe Lo RussoH-Index: 20
view all 12 authors...
: Aim: A minority of patients gains advantage from immunotherapy (IO). Predictive variables of long-term benefit (LTB) are incompletely understood. Materials & methods: We retrospectively collected data about metastatic non-small-cell lung cancer patients treated with IO from April 2013 to July 2017. We defined LTB to IO as complete response (CR), partial response (PR) or disease stability as best response and maintaining it for ≥12 months. Results: Thirty-five of the 147 patients had LTB. More ...
3 CitationsSource
#1Martina ImbimboH-Index: 16
#2Salvatore AlfieriH-Index: 14
Last. Paolo BossiH-Index: 39
view all 15 authors...
ObjectiveThere is no consensus on the follow-up modalities in patients with head and neck cancer. This study aims to describe the pattern and survival outcomes of recurrences/second primary cancers...
7 CitationsSource
#1Claudia ProtoH-Index: 19
#2Diego SignorelliH-Index: 18
Last. Annalisa TramaH-Index: 28
view all 16 authors...
Structured abstract Background Age, sex, stage, histotype and surgery are the most recognized prognostic factors for malignant pleural mesothelioma (MPM). Tumour volume (TV) was suggested as alternative prognostic evaluation. We aimed to assess the prognostic role of TNM vs TV and number of pleural sites (NPS). Materials and methods Information on stage, TV and NPS were collected for 52 MPM patients (pts) at our Institution from 2009 to 2012. Baseline CT scan was performed to define TNM, TV and ...
1 CitationsSource
#1Giulia GalliH-Index: 10
#1Giulia GalliH-Index: 92
Last. Giuseppe Lo RussoH-Index: 20
view all 15 authors...
Abstract Objectives Immunotherapy (IO) is effective in metastatic Non Small Cell Lung Cancer (NSCLC). Gut microbiota has an impact on immunity and its imbalance due to antibiotics may impair the efficacy of IO. We investigated this topic in a case series of NSCLC patients treated with IO. Materials and Methods Data about all metastatic NSCLC patients treated with IO between 04/2013 and 01/2018 were collected. Patients were stratified according to antibiotic use during the Early IO Period (EIOP),...
24 CitationsSource
#1Diego SignorelliH-Index: 18
#2Roberto FerraraH-Index: 19
Last. Arsela PrelajH-Index: 11
view all 17 authors...
9106Background: Immune-checkpoints inhibitors (ICIs) have clearly improved prognosis of metastatic lung squamous carcinoma and adenocarcinoma, while their benefit remains uncertain in patients (pts...
3 CitationsSource
#1Claudia ProtoH-Index: 19
#2Roberto FerraraH-Index: 19
Last. Marina Chiara GarassinoH-Index: 41
view all 15 authors...
Abstract Immunotherapy has dramatically changed the therapeutic scenario in treatment naive advanced non-small cell lung cancer (NSCLC). While single agent pembrolizumab has become the standard therapy in patients with PD-L1 expression on tumor cells ≥ 50%, the combination of pembrolizumab or atezolizumab and platinum-based chemotherapy has emerged as an effective first line treatment regardless of PD-L1 expression both in squamous and non-squamous NSCLC without oncogenic drivers. Furthermore, d...
46 CitationsSource
#1Giulia GalliH-Index: 10
#2Claudia ProtoH-Index: 19
Last. G. Lo RussoH-Index: 1
view all 13 authors...
1 CitationsSource
#1Arsela PrelajH-Index: 11
#1A. PrelajH-Index: 2
Last. Claudia ProtoH-Index: 19
view all 15 authors...
2 CitationsSource